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Abstract: Esophageal adenocarcinoma and its precursor, Barrett’s esophagus, are rapidly rising 
in incidence. This review serves to highlight the role of pharmacologic, endoscopic, and surgical 
intervention in the management of Barrett’s esophagus, which requires acid suppression and 
endoscopic assessment. Treatment with a proton pump inhibitor may decrease acid exposure 
and delay the progression to dysplasia. Patients who require aspirin for cardioprotection or 
other indications may also benefit in terms of a protective effect against the development of 
esophageal cancer. However, without other indications, aspirin is not indicated solely to prevent 
cancer. A careful endoscopic examination should include assessment of any visible lesions in a 
Barrett’s segment. An expert gastrointestinal pathologist should confirm neoplasia in the setting 
of Barrett’s esophagus. For those patients with high-grade dysplasia or intramucosal carcinoma, 
careful consideration of endoscopic therapy or surgical therapy must be given. All visible lesions 
in the setting of dysplasia should be targeted with focal endoscopic mucosal resection for both 
accurate histopathologic diagnosis and treatment. The remainder of the Barrett’s epithelium 
should be eradicated to address all synchronous and metachronous lesions. This may be done 
by tissue acquiring or nontissue acquiring means. Radiofrequency ablation has a positive 
benefit-risk profile for flat Barrett’s esophagus. At this time, endoscopic therapy is not indicated 
for nondysplastic Barrett’s esophagus. Esophagectomy is still reserved for selected cases with 
evidence of lymph node metastasis, unsuccessful endoscopic therapy, or with high-risk features 
of high-grade dysplasia or intramucosal carcinoma.
Keywords: Barrett’s esophagus, high-grade dysplasia, esophagectomy, ablation, endoscopic 
mucosal resection
Introduction
The incidence of esophageal adenocarcinoma has risen dramatically over the last 
30 years.1 The mortality rate from esophageal adenocarcinoma is dismal, with 5-year 
survival rates for advanced-stage adenocarcinoma being ,15%.2 The presence of 
Barrett’s metaplasia is the single most important risk factor for esophageal adeno-
carcinoma, with a 30-fold increase in risk over the general population.3 Acid reflux 
is believed to play a critical role in the development of Barrett’s esophagus. The 
progression to esophageal adenocarcinoma is based on the sequence of changes from 
normal squamous epithelium to Barrett’s esophagus to dysplasia to cancer. The rate 
of progression from nondysplastic Barrett’s esophagus to esophageal adenocarcinoma 
is approximately 0.5% per year.4 The key to prevention and early treatment of esopha-
geal adenocarcinoma is the detection and eradication of dysplasia found in Barrett’s 
  epithelium. High-grade dysplasia is currently the best marker to identify which patients Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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are at risk of progressing to esophageal adenocarcinoma. 
This review serves to highlight the role of pharmacologic, 
endoscopic, and surgical intervention in the management of 
Barrett’s esophagus.
Barrett’s esophagus is diagnosed by both endoscopy 
and histology. On endoscopy, it is suspected by the pres-
ence of salmon-colored columnar mucosa appearing in the 
esophagus. These areas should be biopsied, which is neces-
sary to identify specialized intestinal metaplasia, which is a 
histopathologic diagnosis, widely defined by the presence 
of goblet cells on biopsy. Dysplasia is defined as cytologic 
and architectural atypia without evidence of invasion past 
the basement membrane. The distinction between low-grade 
dysplasia and high-grade dysplasia is based on the sever-
ity of atypia and suggestion of neoplastic transformation. 
Intramucosal carcinoma refers to tumor that has invaded 
past the basement membrane but is superficial to the lamina 
propria. Submucosal carcinoma histologically invades past 
the muscularis mucosa into the submucosa, but does not 
extend into the muscularis propria. Distinguishing the vari-
ous stages of progression to cancer as intestinal metaplasia, 
low-grade dysplasia, high-grade dysplasia, intramucosal 
carcinoma, and submucosal carcinoma is crucial in guiding 
therapeutic intervention.
Medical therapy
PPi and H2RA: regression of Barrett’s 
esophagus
Use of the antisecretory medications, proton pump inhibi-
tors (PPIs) and histamine receptor antagonists (H2RAs), has 
offered hope of achieving reversal of the metaplastic epithe-
lium characteristics of Barrett’s esophagus. Several observa-
tional and prospective studies have assessed for regression of 
Barrett’s esophagus in response to PPIs. Studies have defined 
regression as reduction in overall length of the metaplastic 
segment in the distal esophagus. Partial regression has been 
demonstrated by appearance of islands of squamous epi-
thelium within the metaplastic columnar lining. It has been 
surmised that a reduction in the surface area of Barrett’s 
esophagus would lower the risk of cancer. Studies evaluating 
regression of Barrett’s esophagus have yielded inconsistent 
results. In studies of patients treated with H2 blockers, sig-
nificant regression of Barrett’s esophagus was not noted.5–7 
Thus, acid suppression with H2RA has not proved effective 
in inducing regression in Barrett’s esophagus.
Since the inception of the PPIs in 1989, most studies on 
Barrett’s esophagus have focused on these agents. Several 
studies have suggested partial regression, as evidenced by 
appearance or enlargement of squamous islands. Upwards of 
half of patients on PPI therapy have demonstrated develop-
ment of new squamous islands or increasing number and size 
of islands.6,8–11 The significance of squamous islands remains 
unclear because metaplasia may still underlie the islands, and 
the relatively modest reduction in surface area of Barrett’s 
esophagus at the sites of squamous islands may not decrease 
the overall risk of cancer in any significant way. Studies of 
PPI therapy have yielded conflicting data with respect to 
reduction in length of Barrett’s esophagus. Although some 
studies have demonstrated a decrease length in the Barrett’s 
segment,7,11,12 other studies have not demonstrated the same 
results, including some with high-dose PPIs.10,13,14
The incidence of complete regression in response to PPIs 
has been reported as approximately 2.4%15 in studies gener-
ally including only long-segment Barrett’s esophagus and 
reported as 7.1% in a study including short-segment Barrett’s 
esophagus.16 A small number of prospective studies have 
assessed if normalization of acid exposure leads to regression. 
Based on a limited number of studies, it appears that control 
of esophageal pH by PPIs may be associated with regression 
of Barrett’s esophagus, although control of pH alone may not 
be sufficient to cause significant regression.12,14
PPi and H2RA: progression to dysplasia 
and esophageal adenocarcinoma
Studies suggest that acid reflux plays a key role in the progres-
sion to dysplasia and esophageal adenocarcinoma, although 
this role in malignant progression is unclear. When compared 
with H2RA, PPI therapy has been shown to be more effica-
cious in preventing the progression of Barrett’s esophagus to 
both dysplasia and esophageal adenocarcinoma.17,18
In observational studies, PPI therapy has been shown to 
be associated with a lower risk of developing low-grade dys-
plasia, high-grade dysplasia, and esophageal adenocarcinoma. 
A study by El Serag et al found the incidence of any grade 
dysplasia to be significantly lower amongst those receiving 
PPIs after a diagnosis of Barrett’s esophagus compared with 
those not treated by PPIs.18 When considering incidence of 
high-grade dysplasia or esophageal adenocarcinoma specifi-
cally, Nguyen et al demonstrated a lower incidence amongst 
patients being prescribed versus not being prescribed a PPI 
(7.4% versus 14.1%).19 It is unclear where in the metaplasia-
dysplasia-esophageal adenocarcinoma sequence that PPIs may 
exert their greatest effect, but there is some evidence that PPIs 
may delay progression from metaplasia to dysplasia. Studies 
suggest that initiating PPI therapy soon after the diagnosis of 
Barrett’s esophagus may prevent this progression.18,20Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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NSAiDS and aspirin
Nonsteroidal anti-inflammatory drug (NSAID) and aspirin 
use has previously been associated with a decreased risk of 
developing colon adenocarcinoma,21,22 and there has been 
interest in their role in preventing progression of Barrett’s 
esophagus. NSAIDs and aspirin exert their effects via 
inhibition of COX-1 and COX-2 enzymes. COX-2 enzyme 
activity contributes to cancer growth in several ways, such 
as inhibition of apoptosis and stimulation of angiogenesis.23 
COX-2 inhibition has been shown to suppress cell growth 
and increase apoptosis in Barrett’s esophagus-associated 
esophageal adenocarcinoma cell lines.24 Overexpression 
of COX-2 has been demonstrated in patients with reflux 
esophagitis, Barrett’s esophagus, dysplasia, and esophageal 
adenocarcinoma.25,26
A study by Vaughan et al showed that current NSAID 
(including aspirin) users had an 80% reduced risk of esopha-
geal adenocarcinoma compared with never-users of NSAIDs, 
with the 5-year incidence of esophageal adenocarcinoma 
being 6.6% versus 14.3% in current versus never-users.27 
Additionally, a review of nine studies found a protective 
association between NSAIDs/aspirin use and esophageal 
adenocarcinoma, and showed that patients with exposure to 
NSAIDs or aspirin had a 33% odds reduction of developing 
esophageal adenocarcinoma.22 Thus, multiple studies dem-
onstrate a protective association between NSAID/aspirin use 
and development of esophageal adenocarcinoma.
NSAID/aspirin may protect against esophageal adenocar-
cinoma either by preventing development of Barrett’s esopha-
gus or by preventing progression from Barrett’s esophagus to 
esophageal adenocarcinoma. In a retrospective study, NSAID 
use was not found to be higher in Barrett’s esophagus patients 
versus esophageal adenocarcinoma patients. However, aspirin 
and NSAID use was lower in both of these groups compared 
with controls without Barrett’s esophagus. If there is a true 
protective effect of NSAIDs, this study suggests it may occur 
prior to the development of Barrett’s esophagus.28
PPI use is widespread in patients with reflux, and thus 
associations of NSAID use and malignant progression are 
often in the setting of concomitant PPI use. In one study 
of patients with at least one filled NSAID/aspirin prescrip-
tion, the majority of whom also had at least one filled PPI 
prescription, a reduced risk of esophageal adenocarcinoma 
was demonstrated.29 It is possible that a protective effect is 
due to a combined effect of each medication.
The findings of the majority of these studies are largely 
associations and observations, because there are signifi-
cant barriers in conducting a large clinical trial evaluating 
NSAIDs/aspirin as potential chemoprotective agents. At this 
time, it is the position of the American Gastroenterological 
Association to advise against using aspirin solely to prevent 
esophageal adenocarcinoma in the absence of other cardio-
vascular indications.30
Celecoxib
COX-1 is responsible for maintaining the integrity of the 
gastrointestinal mucosa, and COX-1 inhibition is associ-
ated with an increased incidence of upper gastrointestinal 
complications, such as peptic ulcer disease.31 Thus, selec-
tive inhibition of COX-2 by celecoxib may be of benefit 
with fewer side effects. The Chemoprevention for Barrett’s 
Esophagus Trial, a Phase IIB, multicenter, randomized trial 
of celecoxib in patients with Barrett’s esophagus and low-
grade dysplasia or high-grade dysplasia, randomly assigned 
222 patients to treatment with celecoxib or placebo. After 
48 weeks, no significant difference was observed in the 
proportional change of biopsy samples with dysplasia or 
cancer between the groups.32 This trial does not suggest 
that celecoxib prevents progression of Barrett’s esophagus, 
although further studies are needed.
Endoscopic surveillance and detection 
of neoplasia
Routine surveillance of Barrett’s esophagus is paramount in 
early detection of neoplasm and institution of appropriate 
therapies. Standard surveillance protocols call for four quad-
rant biopsies performed at every 1–2 cm intervals from the 
proximal gastroesophageal junction extending to the squamo-
columnar junction. Guidelines proposed by the American 
College of Gastroenterology provide intervals for surveillance 
depending on the pathology.33 If no dysplasia is detected, a 
second esophagogastroduodenoscopy with biopsies should be 
performed within a year, and then at 3-yearly intervals. If low-
grade dysplasia is found, a repeat esophagogastroduodenos-
copy with biopsies should be performed within 6 months, and 
then at 1-yearly intervals until no dysplasia is found on two 
consecutive esophagogastroduodenoscopies. In the case of 
high-grade dysplasia, repeat esophagogastroduodenoscopy 
with four quadrant biopsies at 1 cm intervals should be per-
formed within 3 months, and then at regular 3-monthly inter-
vals to monitor for esophageal adenocarcinoma if no therapy 
is performed. Any mucosal irregularity warrants endoscopic 
mucosal resection. All dysplastic lesions should be confirmed 
by an expert gastrointestinal pathologist.
The Prague C and M criteria, first introduced in 2004, 
provide a standardized, validated, and reliable   classification Therapeutics and Clinical Risk Management 2011:7
Diagnosis of Barrett’s esophagus 
PPI therapy
Endoscopic surveillance with biopsy 
HGD IMC SMI or LMN 
Focal EMR (for visible
lesions and mucosal
irregularity)
Eradication of the
remainder of Barrett’s
epithelium 
Esophagectomy* 
EMR
Esophagectomy* 
Esophagectomy 
A diagnosis of neoplasia should be 
confirmed by an expert GI pathologist.
Figure 1 Management of patients with Barrett’s esophagus with neoplasia.34
Note: *For high risk cases, ie, HGD from multiple levels, poorly differentiated 
tumor, invasion of lymphatics, blood vessels, or neural structures.
Abbreviations: eMR, endoscopic mucosal resection; Gi, gastrointestinal; PPi, proton 
pump  inhibitor;  HGD,  high-grade  dysplasia;  iMC,  intramucosal  carcinoma;  SMi, 
submucosal invasion; LNM, lymph node metastasis.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
450
Konda and Dalal
  system for the endoscopic description of   Barrett’s   esophagus.35 
The key steps involve: identifying the gastroesophageal 
junction by recognizing key landmarks, such as the proxi-
mal margin of the gastric mucosal folds, pinch at the distal 
esophagus, and diaphragmatic hiatus; defining the proximal 
extent of circumferential columnar-appearing mucosa in 
  centimeters above the gastroesophageal junction and report-
ing this distance as the C value, defining the maximum 
extent of any tongues of columnar-appearing mucosa above 
the gastroesophageal junction and reporting this distance as 
the M value.
Surveillance protocols utilizing white light examination 
have been essential in recognition of lesions, but dysplastic 
lesions are still often missed on biopsy. A detailed exami-
nation of the Barrett’s segment with high-resolution white 
light endoscopy is critical in the assessment for neoplasia. 
Additional imaging modalities may offer improved mucosal 
visualization and assessment of structural changes, thereby 
allowing for identification of abnormal areas and appropri-
ately targeting biopsies. Narrow band imaging is a technique 
that utilizes narrowed bandwidths of blue and green light 
to improve visibility of microstructural and capillary pat-
terns in Barrett’s esophagus, without using dyes. Shorter 
wavelength light has superficial penetration, and is ideal for 
mucosal imaging. Narrow band imaging with   magnification 
has been shown to have high sensitivity for diagnosing intes-
tinal metaplasia and high-grade dysplasia on the basis of 
irregular mucosal pit patterns or irregular microvasculature, 
but poor specificity.36 Clinically, this may reduce the need for 
multiple random biopsies and increase the histologic yield 
of dysplasia. However, addition of narrow band imaging to 
high-resolution white light endoscopy has not been shown 
to improve interobserver agreement or increase yield in 
identifying early neoplasia.37
Additional techniques are being studied and utilized 
at high-volume centers. Autofluorescence imaging uses 
endogenous tissue substances (fluorophores), which 
become excited by light and emit light of longer wave-
length than the exciting light. With autofluorescence 
imaging, normal   esophagus and nondysplastic Barrett’s 
esophagus appears green, whereas areas of high-
grade dysplasia/adenocarcinoma appear blue or violet. 
However, it is associated with a high false-positive rate.38 
Confocal laser microendoscopy allows for targeting 
of suspicious areas for biopsy and real-time histologic 
assessment of the epithelium. Both the epithelium and 
subepithelial vascular structures can be imaged at various 
depths,39 and confocal laser microendoscopy has been shown 
to increase diagnostic yield of endoscopically inapparent 
neoplastic epithelium significantly compared with standard 
  endoscopy.40 Finally, in chromoendoscopy, a chemical agent 
such as methylene blue, indigo carmine, or acetic acid is 
applied to the esophageal mucosa to distinguish epithelial 
subtypes based on different pit patterns.
Although the gold standard for diagnosis is histology, 
there exists high interinterpreter variability in diagnos-
ing dysplasia.41–43 Inherent to the challenge in diagnosing 
dysplasia is that neoplastic transformation represents a 
biologic and histologic continuum, but the pathologist 
must discretely categorize lesions as Barrett’s esophagus, 
low-grade dysplasia, high-grade dysplasia, intramucosal 
carcinoma, or submucosal carcinoma. Cytologic features of 
dysplasia may be confused with inflammatory changes, and 
often limitations in sample size, depth, and potential crush 
artifact make it difficult to distinguish reliably between 
various stages of disease based on a single biopsy specimen. 
Prior to embarking on any therapy for Barrett’s associated 
neoplasia, the dysplasia should be confirmed by an expert 
gastrointestinal pathologist.
Furthermore, endoscopic evaluation should include spe-
cific attention to any visible lesions. Rigorous assessment of 
the remainder of the Barrett’s epithelium should be done to 
evaluate for any occult neoplasia. Visible lesions, including 
mucosal irregularities, in the setting of dysplasia should be 
targeted with endoscopic mucosal resection for accurate Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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histopathologic staging. Larger and more intact specimens 
from endoscopic resection may allow pathologists to make 
a more reliable staging diagnosis. The effect of staging by 
endoscopic mucosal resection specimens is demonstrated 
by our center’s complete Barrett’s eradication endoscopic 
mucosal resection study, which upstaged seven of 49 (14%) 
and downstaged 15 of 49 (31%) cases by endoscopic mucosal 
resection compared with pretreatment endoscopic biopsies.44 
Additionally, in a large study comparing Barrett’s esophagus 
patients undergoing endoscopic mucosal resection versus 
biopsy, significantly greater interobserver agreement on the 
diagnosis of dysplasia was demonstrated for endoscopic 
mucosal resection specimens.45
Endoscopic therapy
Endoscopic therapy is now an established form of treatment 
at referral centers for neoplasia associated with Barrett’s 
esophagus. These modalities offer an organ-sparing and 
safer approach compared with esophagectomy, and patients 
with high-grade dysplasia or intramucosal carcinoma may 
be appropriate candidates for treatment (see Figure 1). 
Endoscopic therapy does not confer the same benefit for 
low-grade dysplasia or nondysplastic Barrett’s esophagus, 
given the potential complications of therapy and the lower 
risk of malignant transformation in these patients. Future 
risk stratification may enable us to select which patients may 
benefit from intervention in these populations.
The risk of Barrett’s esophagus patients with high-grade 
dysplasia harboring occult invasive esophageal adenocarci-
noma is estimated at around 40%,46 and this has previously 
supported prophylactic esophagectomy over endoscopic 
monitoring. A review of the literature reporting rates of 
invasive cancer in 441 patients who underwent prophylactic 
esophagectomy for high-grade dysplasia demonstrated a 
pooled average rate of 39.9%. This rate was decreased to 
12.7% when applying the strict definition of invasive cancer 
as being tumor invading the submucosa, and most patients 
were actually found to have intramucosal carcinoma.47 
Intramucosal carcinoma carries a #3% risk of nodal 
metastasis,47–51 and thus may be amenable to local endoscopic 
treatment.44,52 By comparison, submucosal invasion carries a 
higher risk of nodal metastasis, thus surgery and/or systemic 
therapy is required.48,53 With accurate distinction between 
high-grade dysplasia and intramucosal carcinoma from 
invasive cancer, endoscopic therapy may instead be a more 
appropriate alternative than esophagectomy.
Endoscopic therapy for high-grade dysplasia or intramu-
cosal carcinoma is performed with the goal of preserving the 
esophagus while ablating all Barrett’s esophagus epithelium 
to prevent neoplastic progression. This includes ablating both 
dysplastic and nondysplastic epithelium due to the risk of 
developing synchronous or metachronous lesions in remain-
ing metaplastic Barrett’s esophagus tissue.54 Endoscopic 
therapies include tissue acquiring and nontissue acquiring 
modalities. Endoscopic resection, including both endoscopic 
mucosal resection and endoscopic mucosal dissection is a 
tissue-acquiring modality, and allows for histopathologic 
diagnosis. Nontissue acquiring modalities include photo-
dynamic therapy, radiofrequency ablation, and cryotherapy, 
which treat by tissue destruction.
Endoscopic resection
Endoscopic mucosal resection and endoscopic mucosal 
dissection allow for removal of tissue and establishing a 
histopathologic diagnosis. Endoscopic mucosal resection can 
be performed using the band ligation or cap technique, both 
of which involve endoscopic suction with a friction fitted 
cap to create a pseudopolyp. Endoscopic mucosal resection 
can be performed focally or for the entirety of the Barrett’s 
epithelium. Focal endoscopic mucosal resection can be per-
formed on suspicious-appearing lesions, but is associated 
with high recurrence rates, ranging from 14%–47% in the 
studies.55–62 These high rates are due in part to multifocal 
synchronous lesions previously missed by biopsy, as well as 
the metachronous development of new lesions.63 Five-year 
follow-up data for 231 Barrett’s esophagus patients with 
intramucosal carcinoma demonstrated a 95.7% complete 
response rate in one study.64
Complete Barrett’s eradication endoscopic mucosal 
resection also known as circumferential endoscopic mucosal 
resection, stepwise radical endoscopic resection, or wide area 
endoscopic mucosal resection, involves resecting the entire 
Barrett’s segment. This minimizes the risk of potential devel-
opment of synchronous or metachronous lesions. Complete 
response from complete Barrett’s eradication endoscopic 
mucosal resection has been in the range of 76%–100% in 
studies.44,52,65–67 In a multicenter European cohort study, 169 
Barrett’s esophagus patients with high-grade dysplasia or 
early carcinoma underwent complete endoscopic mucosal 
resection. After 27 months of follow-up, remission of neo-
plasia was demonstrated in 97.5% of patients, and complete 
elimination of metaplasia in 85%. The recurrence rate for 
metachronous lesions was 1.8%.67
Endoscopic submucosal dissection involves marking the 
boundary of a lesion with cautery, injecting a viscous fluid into 
the submucosal space to provide a cushion under the lesion, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
452
Konda and Dalal
followed by dissection using a cutting device.68 Endoscopic 
mucosal dissection is utilized for suspicious-appearing lesions 
larger than 1.5 cm, and employs an en bloc dissection. This 
approach may be considered for lesions at the gastroesophageal 
junction or gastric cardia, where it is often difficult to create 
a pseudopolyp.63 The recurrence rate was 0% in one study of 
15 Barrett’s esophagus patients who underwent endoscopic 
mucosal dissection at the gastroesophageal junction for 
esophageal adenocarcinoma.69 One potential barrier to this 
approach is reflux-induced submucosal fibrosis in the distal 
esophagus.63 Complications of endoscopic mucosal resection 
include stricture formation in nearly half of cases, bleeding, and 
rarely, perforation.44,52,65–67,70 However, stenoses and bleeding 
are complications that can be endoscopically treated.
Radiofrequency ablation
Radiofrequency ablation of a Barrett’s esophagus segment 
can be done circumferentially using a balloon-based catheter 
or locally using a focal device. Lesions are treated by applica-
tion of direct thermal energy with electrodes embedded in 
the circumferential balloon or focal device. There are two 
separate applications of thermal energy, with scraping of 
treated tissue between the first and second ablation to ensure 
adequate and uniform thermal contact. Potential complica-
tions of radiofrequency ablation include noncardiac chest 
pain, nontransmural lacerations, and stricture formation.44
Nondysplastic Barrett’s esophagus has demonstrated 
regression in response to radiofrequency ablation in large 
clinical studies. In the Ablation of Intestinal Metaplasia 
(AIM) study, a 70% complete remission rate of Barrett’s 
metaplasia was demonstrated in the circumferentially 
treated group at 1-year follow-up. Stricture formation did 
not occur, and no buried Barrett’s esophagus was found in 
the 4306 biopsy specimens.71 The AIM-II trial at 2.5-year 
follow-up demonstrated complete eradication in 98.4% of 
patients treated with circumferential radiofrequency abla-
tion followed by focal radiofrequency ablation of remaining 
  Barrett’s esophagus.72 Five-year outcomes from the AIM-II 
trial demonstrated complete remission in 92% of the partici-
pating patients, with no buried glands, dysplasia, strictures, 
or serious adverse events reported.73
Radiofrequency ablation has been shown to be effica-
cious in the treatment of dysplastic Barrett’s esophagus as 
well. In a recent landmark randomized trial, patients with 
high-grade dysplasia demonstrated complete eradication in 
81.0% of cases treated with radiofrequency ablation com-
pared with 19.0% in controls. Overall, 77.4% of patients 
in the ablation group demonstrated complete eradication 
of intestinal   metaplasia, compared with 2.3% in controls. 
Disease   progression was lower in the ablation group (3.6% 
versus 16.3%) and fewer cancers were noted (1.2% versus 
9.3%). The rate of esophageal stricture in the radiofrequency 
ablation group was 6%, which is much lower than the rate 
associated with endoscopic mucosal resection.74 Similarly, 
1-year follow-up in another study of 142 patients with high-
grade dysplasia demonstrated a remission rate of 90.2%.75
The efficacy of utilizing both endoscopic mucosal resec-
tion and radiofrequency ablation in patients with dysplastic 
Barrett’s esophagus has been evaluated. In a multicenter 
European trial of 24 patients with Barrett’s esophagus, vis-
ible lesions were endoscopically resected, followed by serial 
radiofrequency ablation. Neoplasia and metaplasia was eradi-
cated in 95% and 88% of cases, respectively, and recurrence 
of neoplasia after 22 months of median follow-up was 0%.76 
Efficacy of focal endoscopic mucosal resection followed by 
radiofrequency ablation was also demonstrated in a trial of 
patients with longer Barrett’s esophagus segments (. 10 cm), 
with complete response rates of 83% and 79% for neoplasia 
and intestinal metaplasia, respectively, and no recurrence of 
neoplasia during 9.1 months of mean follow-up.
The above studies each evaluated the efficacy of focal 
endoscopic mucosal resection followed by radiofrequency 
ablation. Whether this approach or stepwise radical endo-
scopic resection alone is more efficacious and has fewer 
complications was evaluated by van Vilsteren et al in a 
randomized trial. Patients in the stepwise radical endo-
scopic resection group underwent focal endoscopic mucosal 
resection followed by serial endoscopic mucosal resection, 
whereas patients in the endoscopic mucosal resection/
radiofrequency ablation group underwent focal endoscopic 
mucosal resection followed by radiofrequency ablation. 
Rates of complete remission were similar between the groups 
(100% for stepwise radical endoscopic resection versus 96% 
for endoscopic mucosal resection/radiofrequency ablation). 
However, the stepwise radical endoscopic resection group 
had a much higher rate of stenosis (88%) and required more 
endoscopic dilations.70
Photodynamic therapy
Photodynamic therapy employs a light-sensitizing reaction 
to produce oxygen radicals, which destroy targeted cells. 
A photosensitizer such as porfimer sodium or 5-  aminolevulinic 
acid is administered intravenously 48–72 hours prior to 
endoscopy and accumulates in esophageal tissue prior to light 
activation. Subsequently, a bare cylinder, or balloon-based 
diffusing light fibers, are introduced endoscopically into the Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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esophagus, and activation of the photosensitizer occurs in the 
dysplastic cells. Free oxygen radicals are generated which 
eventually induce cellular apoptosis.77
Studies suggest that photodynamic therapy is an effective 
treatment modality for eradication of Barrett’s esophagus 
with high-grade dysplasia and intramucosal carcinoma. 
Overholt et al retrospectively evaluated 103 patients with 
low-grade dysplasia, high-grade dysplasia, and intramucosal 
carcinoma, and intention-to-treat success rates were 92.9%, 
77.5%, and 44.4% for each respective group after a mean of 
50 months. Stricture formation overall occurred in 30% of 
cases.78 Pech et al prospectively followed 66 patients with 
high-grade dysplasia or intramucosal carcinoma treated with 
5-aminolevulinic acid photodynamic therapy and followed for 
a median of 37 months. Complete response was demonstrated 
in 97% of the high-grade dysplasia group and 100% of the 
intramucosal carcinoma group.79
Limitations of photodynamic therapy include additional 
time required to administer photosensitizers 2–3 days prior to 
therapy. Given the systemic distribution of the photosensitiz-
ers, patients must also avoid direct sunlight up to 6 weeks due 
to potential photosensitivity reactions.77 Other adverse effects 
include noncardiac chest pain and symptomatic stricture 
formation. Stricture formation was reported in one study to 
occur in 27% of patients, with significant risk factors being 
endoscopic mucosal resection therapy before photodynamic 
therapy, a prior history of an esophageal stricture, and the 
number of photodynamic therapy applications.80 Another 
concern is the potential development of subsquamous 
Barrett’s esophagus glands, because cases of esophageal 
adenocarcinoma arising from such glands after photodynamic 
therapy have been reported.78,81 Given these limitations, pho-
todynamic therapy has fallen out of favor in recent years, and 
referral centers have adopted endoscopic mucosal resection 
and radiofrequency ablation as the preferred endoscopic 
treatment modalities for Barrett’s esophagus.
Cryotherapy
The latest endoscopic treatment modality is cryotherapy, 
which utilizes a spray catheter introduced via the endoscope 
and directed at targeted abnormal tissue. Sprayed liquid 
nitrogen or carbon dioxide is applied, which produces freeze-
thaw cycles that result in tissue destruction by intracellular 
disruption or tissue ischemia, while minimizing fibrosis.82 
Orogastric decompression tube placement allows for expul-
sion of excess gas and prevention of inadvertent perforation. 
Dumot et al enrolled patients with Barrett’s esophagus and 
high-grade dysplasia or intramucosal carcinoma who were 
deemed inoperable or had refused esophagectomy into a 
trial. Thirty patients underwent cryotherapy, and afterwards 
27 (90%) demonstrated pathologic downstaging. After 
1-year median follow-up, elimination of cancer or downstag-
ing of dysplasia was demonstrated in 68% of high-grade 
dysplasia and 80% of intramucosal carcinoma patients.83 
In a more recent trial, patients with high-grade dysplasia 
(n = 17) demonstrated a 94% regression rate while patients 
with intramucosal carcinoma (n = 4) and early esophageal 
adenocarcinoma (n = 3) demonstrated a 100% regression 
rate. Complete response to intestinal metaplasia occurred 
in 53% with high-grade dysplasia, 75% with intramucosal 
carcinoma, and 67% with esophageal adenocarcinoma.84 In a 
third study of 60 patients with high-grade dysplasia, 97% had 
complete eradication of high-grade dysplasia, 87% had com-
plete eradication of all dysplasia with persistent metaplasia, 
and 57% had complete eradication of all metaplasia.85
The safety profile of cryotherapy appears to be favorable. 
From the above series, the overall incidence of stricture for-
mation was 9/114 patients (7.9%),83–85 which is lower than 
the reported rates for endoscopic mucosal resection and 
photodynamic therapy. Perforation occurred in a patient with 
Marfan syndrome. Other less serious adverse effects included 
chest pain, dysphagia, odynophagia, and sore throat.84 While 
cryotherapy appears safe, well tolerated, and efficacious 
for the treatment of high-grade dysplasia and intramucosal 
carcinoma in Barrett’s esophagus, there are no randomized 
trials comparing it with other modalities. Furthermore, unlike 
the long-term complete response rates demonstrated for 
endoscopic mucosal resection, data on long-term efficacy 
of cryotherapy is lacking.
Post-therapy surveillance
Current clinical practice requires lifelong surveillance with 
periodic histologic sampling of eradicated Barrett’s esopha-
gus to monitor for recurrence, the presence of buried (sub-
squamous) glands/metaplasia, and progression to neoplasia. 
As mentioned, photodynamic therapy has been associated 
with subsquamous Barrett’s esophagus glands that possess 
neoplastic potential,78–81 thus necessitating sufficient depth of 
biopsy specimens to assess for this risk. Recent studies suggest 
that biopsy specimens are adequate to assess for buried glands 
and intestinal metaplasia. Secondary analysis of the AIM dys-
plasia trial looked at 5648 biopsy specimens from 113 patients 
who underwent radiofrequency ablation or sham procedures. 
Biopsy specimens demonstrated a similar rate of subepithelium 
between both groups (78.4% for radiofrequency ablation group 
versus 79.1% for sham group).86 Follow-up of the AIM-II trial Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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demonstrated that biopsies at 5 years revealed focal metaplasia 
in 8% of patients, demonstrating the importance of surveillance 
in identifying persistent or recurrent disease.
Surgical management
esophagectomy
Until the past decade, esophagectomy for Barrett’s esophagus 
with high-grade dysplasia and intramucosal carcinoma had 
been the traditional standard. Surgery allows for accurate 
staging and assessment of adequacy by looking for negative 
margins and lymph nodes. Complete resection of the entire 
Barrett’s segment is done in cases of unsuspected multifo-
cal disease and to minimize the risk of metachronous lesion 
development in residual Barrett’s.87 Recently, there has been 
a shift to treating high-grade dysplasia and intramucosal car-
cinoma with endoscopic therapies, but submucosal invasion 
remains an indication for esophagectomy. Esophagectomy 
is still reserved for select cases with evidence of lymph 
node metastasis, unsuccessful endoscopic therapy, or with 
high-risk features of high-grade dysplasia or intramucosal 
carcinoma.88 High-risk features to consider include high-
grade dysplasia obtained from multiple levels, protruding or 
excavated lesions, poorly differentiated tumors, and invasion 
into lymphatic channels, blood vessels, or neural structures.88 
A patient’s age, comorbidities, and willingness to undergo 
surgery should also be taken into account.
Compared with endoscopic treatment, there is significant 
morbidity and mortality associated with esophagectomy, with 
overall morbidity rates as high as 50% and mortality as high 
as 10%.89 Adverse outcomes include pulmonary complica-
tions, hemorrhage, anastomotic leak, infection, postoperative 
arrythmias, and nerve palsy. When considering the mortality 
rates for esophagectomy, it is important to recognize that most 
studies describe outcomes after surgery for cancer and not 
high-grade dysplasia, and that high-volume centers tend to 
have better outcomes. At high-volume centers with greater 
surgical expertise, the mortality rate from esophagectomy 
for cancer is 2%–3%.90,91 Furthermore, patients with cancers 
tend to be more debilitated preoperatively, and comorbid 
diseases are less frequent in patients with high-grade dys-
plasia alone.92 Esophagectomy performed specifically for 
high-grade dysplasia has a pooled mortality rate of 1%,92 
making it a lower-risk surgery than when performed for 
cancer. The best surgical option for high-grade dysplasia or 
intramucosal carcinoma should produce the least morbidity 
balanced against best long-term survival.
Several studies provide evidence that esophagectomy 
prevents cancer-related mortality in patients with high-grade 
dysplasia and intramucosal carcinoma. In a study at the 
Cleveland Clinic, pathologic review of resection specimens 
revealed high-grade dysplasia in 59 patients and invasive 
  cancer in 50 patients. Operative mortality was 0%, and 
10-year survival was 86% for both groups.93 Overall 5-year 
survival was 83% for all resected high-grade dysplasia 
patients (91% for those without invasion and 68% for those 
with invasion). Operative mortality occurred in one patient 
(2% mortality rate).94 Similar 5-year survival rates of 88% 
and 86% have been reported in similar studies.95,96
Recurrence rates of Barrett’s esophagus or adenocar-
cinoma following esophagectomy have been assessed in a 
limited number of trials. In a study by Chang et al of 34 
Barrett’s esophagus patients with high-grade dysplasia or 
esophageal adenocarcinoma, the cure rate after esophagec-
tomy and 2-year surveillance was 85%, demonstrated by 
having no clinical, radiographic, or endoscopic evidence of 
recurrent esophageal adenocarcinoma or metastasis.97 In a 
study by Wolfsen et al the cure rate for dysplasia or local-
ized esophageal adenocarcinoma was reported to be lower at 
77.8%.98 This highlights the need for continued endoscopic 
surveillance following resection.
Conventional approaches for esophagectomy are transhi-
atal and transthoracic resection. Transhiatal resection without 
thoractomy can be done to prevent respiratory compromise, 
with the incidence of atelectasis or pneumonia being low (2% 
and ,1% of cases, respectively).99 A randomized trial com-
paring 106 patients undergoing transhiatal esophagectomy 
and 114 patients undergoing transthoracic esophagectomy 
with lymphadenectomy demonstrated a significantly lower 
rate of postoperative respiratory complications with the tran-
shiatal approach (27% versus 57%). A trend towards greater 
survival was shown for the transthoracic approach at 5 years 
(39% versus 27%). No significant difference was noted for 
inhospital mortality.100 One potential limitation of the transhi-
atal approach is the inability to retrieve lymph nodes required 
for nodal staging;101 more extensive resection using a transt-
horacic approach with thoracotomy likely improves staging 
accuracy. The needs of the patient (accurate staging versus 
functional status and operative risk) as well as the surgeon’s 
expertise ultimately determine the preferred approach.
Minimally invasive esophagectomy utilizes video-assisted 
or laparoscopic techniques and is a promising approach. 
Minimally invasive esophagectomy has potential advantages 
over open esophagectomy because of a lower incidence of 
pulmonary complications, faster postoperative recovery, 
and decreased length of hospital stay.102   Minimally invasive 
esophagectomy avoids the thoracotomy and   laparotomy, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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thus limiting the extent of surgical trauma and presumably 
reducing postoperative morbidity and increasing quality of 
life.103 However, lymph node retrieval is largely inferior 
to standards of open surgery, and morbidity and mortality 
of minimally invasive esophagectomy is not proven to be 
lower when compared with open esophagectomy at expe-
rienced centers.104 Recommendations favoring minimally 
invasive esophagectomy over open esophagectomy cannot 
be made due to a lack of randomized trials comparing the 
two approaches.
In patients with few comorbidities and an otherwise long 
life expectancy, a vagal-sparing esophagectomy can be con-
sidered to improve outcomes and quality of life. Peyre et al 
demonstrated lower infectious, respiratory, and anastomotic 
complications in patients with high-grade dysplasia or intra-
mucosal carcinoma undergoing this procedure compared with 
transhiatal esophagectomy. Quality of life advantages were 
also demonstrated, with the potential for reduced morbidity 
owing to avoidance of postvagotomy dumping and diarrhea, 
as well as a shorter hospital stay.105 However, lymphadenec-
tomy is not performed with this procedure, so it is not an 
option for patients with submucosal cancer given the need 
for nodal staging. Long-term outcomes data are lacking, thus 
its overall utility remains to be seen.
Antireflux surgery
Antireflux surgery using fundoplication theoretically elimi-
nates acid reflux and provides better control of gastroesopha-
geal reflux disease than PPIs. The concept that adequate 
reflux control following antireflux surgery is necessary to 
reduce the rate of progression of disease is supported by 
studies that suggest progression is significantly more likely to 
occur with a failed fundoplication and persistent reflux.4,106,107 
In the only randomized trial to date comparing antireflux 
surgery and PPIs, 43 patients treated medically and 58 treated 
with antireflux surgery were compared. No significant dif-
ference between the two groups was found with respect to 
preventing progression to dysplasia and adenocarcinoma.108 
Optimal candidates for antireflux surgery include those who 
lack major comorbidities and demonstrate some response 
to PPI therapy.33 Antireflux surgery has not been proven to 
reduce progression of nondysplastic Barrett’s esophagus 
to high-grade dysplasia or adenocarcinoma significantly, 
and does not obviate the need for continued surveillance. 
The decision to pursue antireflux surgery should depend 
on patient preference and the severity of reflux symptoms 
despite PPI therapy, rather than for definitive management 
of intestinal metaplasia.
Conclusion
In summary, the management of Barrett’s esophagus requires 
acid suppression and endoscopic assessment. For patients with 
nondysplastic Barrett’s esophagus, treatment with a PPI may 
decrease acid exposure and delay the progression to dysplasia. 
A careful endoscopic examination should include assessment 
of any visible lesions in a Barrett’s segment. An expert gastro-
intestinal pathologist should confirm neoplasia in the setting 
of Barrett’s esophagus. For those patients with high-grade 
dysplasia or intramucosal carcinoma, careful consideration 
of endoscopic therapy or surgical therapy must be given. All 
visible lesions in the setting of dysplasia should be targeted 
with focal endoscopic mucosal resection for both accurate 
histopathologic diagnosis and for treatment. The remainder of 
the Barrett’s epithelium should also be eradicated to address all 
synchronous and metachronous lesions. This may be done with 
tissue acquiring or nontissue acquiring means. Radiofrequency 
ablation has a positive benefit-risk profile for flat Barrett’s 
esophagus. At this time, endoscopic therapy is not indicated 
for nondysplastic Barrett’s esophagus. Esophagectomy is 
still reserved for selected cases with evidence of lymph node 
metastasis, unsuccessful endoscopic therapy, or with high-risk 
features of high-grade dysplasia or intramucosal carcinoma.
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